about
Role of Exosomal Noncoding RNAs in Lung CarcinogenesissiRNA delivery to the lung: what's new?Novel insights into miRNA in lung and heart inflammatory diseasesDelivery of RNAi Therapeutics to the Airways-From Bench to BedsideAdvanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug DeliveryEmerging therapies targeting intra-organ inflammation in transplantationTranslational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory DiseasesSilencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo.Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium.The impact of extracellular vesicle-encapsulated circulating microRNAs in lung cancer researchPrognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer.Development of small RNA delivery systems for lung cancer therapy.Suppression of autophagy by extracellular vesicles promotes myofibroblast differentiation in COPD pathogenesisAcid-Sensitive Sheddable PEGylated PLGA Nanoparticles Increase the Delivery of TNF-α siRNA in Chronic Inflammation Sites.MicroRNAs as therapeutics for future drug delivery systems in treatment of lung diseases.BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.Alternative approaches for the treatment of airway diseases: focus on nanoparticle medicine.miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells.MicroRNAs as Therapeutic Targets in Lung Disease: Prospects and ChallengesExtracellular Vesicle: An Unknown Environmental Factor for Causing Airway Disease.[Research Progress of Exosomes in Lung Cancer Diagnosis and Treatment].
P2860
Q27000282-D8C3C49E-20DF-4C07-9A06-29DA1F66BFE4Q27022043-8A44C09D-485E-45F5-B28C-E0D3235773D1Q27026348-31E15CD4-FD5C-43ED-BEA6-F175CE654514Q28067306-AF41D670-1556-4613-89A5-A93A382900E4Q28076132-EBC721B9-10F4-4905-AE25-6402A5F1F7BEQ28085496-C8949BC9-A19A-46EA-8705-A1D5D0B03870Q28548580-29C50E8B-9BEA-4C9B-A4D5-BED37188BA28Q33570738-ABF45E79-943D-42BE-9673-2C6AAE41EC75Q33732559-58C8BA55-76FD-411A-BC7C-7FC3B633BD28Q34252557-E477CA5D-F30A-42B7-BDF0-11AA17451102Q34458532-27C1C124-6554-4AD6-9B97-FAA58765D961Q35380932-FFA13E9A-8532-4C8F-BCE4-24AAB9D7290DQ36275264-CAE3A967-A9C7-4DFA-9277-2919651D869EQ37672324-56E3D1DB-7FF7-4A38-A14A-3398DC698183Q38795034-E9261473-528B-4231-B28B-272CC440B21AQ38817806-3147ABFC-BF1C-4414-A793-0AD8D8ECBF5FQ38893756-17A6914C-ED99-490C-83B7-759FD57EA68CQ38905678-80F27AD5-1D6B-4164-8D18-B3CB5E3F4A66Q41434163-5933FC53-915B-431F-8FCA-2E368A7B745BQ42614686-D8B8374F-4BB9-418E-BC8E-8507F0668B91Q53760783-EC818CC3-5E7D-4F33-836F-78E8C9898853
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 February 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
RNAi Therapeutic Platforms for Lung Diseases.
@en
RNAi Therapeutic Platforms for Lung Diseases.
@nl
type
label
RNAi Therapeutic Platforms for Lung Diseases.
@en
RNAi Therapeutic Platforms for Lung Diseases.
@nl
prefLabel
RNAi Therapeutic Platforms for Lung Diseases.
@en
RNAi Therapeutic Platforms for Lung Diseases.
@nl
P2093
P2860
P356
P1433
P1476
RNAi Therapeutic Platforms for Lung Diseases.
@en
P2093
Fumitaka Takeshita
Kazuyoshi Kuwano
Takahiro Ochiya
P2860
P304
P356
10.3390/PH6020223
P50
P577
2013-02-06T00:00:00Z